The trial was defined in a Dow Jones Newswire december 2 article dated.

Biovail comments about Teva Pharmaceutical’s proposed Budeprion XL trial Biovail Company today commented on a proposed clinical trial declared by Teva Pharmaceutical Sectors Ltd recently. The trial was defined in a Dow Jones Newswire december 2 article dated, 2009. Patients will become confined in a scientific setting for a complete period of 24 days wakefulness agent . The content indicates that bioequivalence will be based on the typical statistical requirements of the U.S. Food and Medication Administration . Adverse events should be recorded also. Biovail believes this determination may very well be verified by the proposed new trial. Furthermore, the eight-day treatment intervals in the proposed trial could be too short for a meaningful result clinically, since most antidepressant scientific trials require treatment intervals of at least 28 days.